<DOC>
	<DOC>NCT00850577</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with carboplatin and paclitaxel in the treatment of chemonaive subjects with recurrent or advanced non-squamous NSCLC</brief_summary>
	<brief_title>Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>For additional information, please contact the BMS oncology clinical trial information service at 8552160126 or email MyCancerStudyConnect@emergingmed.com. Please visit www.BMSStudyConnect.com for more information on clinical trial participation. ECOG Performance Status (PS) &lt;=1 Histologically or cytologically confirmed, stage IIIB (malignant pleural effusion), stage IV or recurrent NSCLC Measurable disease by RECIST guidelines Evidence of predominantly squamouscell histology Known CNS metastases Any prior antineoplastic systemic regimens for NSCLC Excessive risk of bleeding (including use of therapeutic anticoagulation) and history of thrombotic or embolic cerebrovascular accident Gross hemoptysis (â‰¥1/2 tsp of red blood) Uncontrolled hypertension Clinically significant cardiovascular disease History of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within the past 6 months Serious nonhealing wound, active peptic ulcer, nonhealing bone fracture, or bleeding skin metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>